These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9989750)

  • 1. Principles of epidemiological research on drug effects.
    Gargiullo PM; Kramarz P; DeStefano F; Chen RT
    Lancet; 1999 Feb; 353(9151):501. PubMed ID: 9989750
    [No Abstract]   [Full Text] [Related]  

  • 2. Principles of epidemiological research on drug effects.
    MacDonald TM; Evans JM; Sullivan F; McMahon AD
    Lancet; 1999 Feb; 353(9151):501-2. PubMed ID: 9989751
    [No Abstract]   [Full Text] [Related]  

  • 3. Principles of epidemiological research on adverse and beneficial drug effects.
    Jick H; García Rodríguez LA; Pérez-Gutthann S
    Lancet; 1998 Nov; 352(9142):1767-70. PubMed ID: 9848368
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    Senn S
    Stat Med; 2009 Dec; 28(30):3754-8; discussion 3759-60. PubMed ID: 19967754
    [No Abstract]   [Full Text] [Related]  

  • 5. Measures of 'exposure needed for one additional patient to be harmed' in population-based case-control studies.
    Hallas J; Christensen RD; Stürmer T; Pottegård A
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):868-74. PubMed ID: 24789145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy Part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association.
    Shapiro S
    J Fam Plann Reprod Health Care; 2008 Jul; 34(3):185-90. PubMed ID: 18577320
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidemiological assessment of drug-induced disease.
    Kaufman DW; Shapiro S
    Lancet; 2000 Oct; 356(9238):1339-43. PubMed ID: 11073036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methodology of epidemiological studies in drug hepatotoxicity].
    Plomteux G
    Sem Hop; 1974 Jun; 50(28):1947-52. PubMed ID: 4374747
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of drug-induced disease.
    Lawson DH
    Br J Clin Pharmacol; 1979 Jan; 7(1):13-8. PubMed ID: 367408
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiological identification and evaluation of hepatic adverse drug reactions.
    Bruppacher R
    Semin Liver Dis; 1995 Aug; 15(3):301-8. PubMed ID: 7491508
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
    Lapeyre-Mestre M; Sapède C; Moore N; ; Bilbault P; Blin P; Chopy D; Evans D; Gueyffier F; Lacoin L; Malbezin M; Micallef J; Morlet-Vigier D; Muller S; Oger E; Plétan Y; Pons G; Verpillat P; Vigneau C
    Therapie; 2013; 68(4):241-52. PubMed ID: 23981262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on: "Desideratum for evidence-based epidemiology".
    Hennessy S; Leonard CE
    Drug Saf; 2015 Jan; 38(1):101-3. PubMed ID: 25511911
    [No Abstract]   [Full Text] [Related]  

  • 13. The promise of pharmacoepidemiology.
    Strom BL
    Annu Rev Pharmacol Toxicol; 1987; 27():71-86. PubMed ID: 3555321
    [No Abstract]   [Full Text] [Related]  

  • 14. Case-population studies in pharmacoepidemiology.
    Capellà D; Pedrós C; Vidal X; Laporte JR
    Drug Saf; 2002; 25(1):7-19. PubMed ID: 11820909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
    Lo Re V; Haynes K; Ming EE; Wood Ives J; Horne LN; Fortier K; Carbonari DM; Hennessy S; Cardillo S; Reese PP; Reddy KR; Margolis D; Apter A; Kimmel SE; Roy J; Freeman CP; Razzaghi H; Holick CN; Esposito DB; Van Staa TP; Bhullar H; Strom BL
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1202-15. PubMed ID: 22763953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 17. Authors' reply to Hennessy and Leonard's comment on "Desideratum for evidence-based epidemiology".
    Overhage JM; Ryan PB; Schuemie MJ; Stang PE
    Drug Saf; 2015 Jan; 38(1):105-7. PubMed ID: 25511912
    [No Abstract]   [Full Text] [Related]  

  • 18. Idiosyncratic drug reactions: the reactive metabolite syndromes.
    Knowles SR; Uetrecht J; Shear NH
    Lancet; 2000 Nov; 356(9241):1587-91. PubMed ID: 11075787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance.
    Feinstein AR
    Clin Pharmacol Ther; 1974 Jul; 16(1):110-23. PubMed ID: 4843239
    [No Abstract]   [Full Text] [Related]  

  • 20. Methods for safety signal detection in healthcare databases: a literature review.
    Arnaud M; Bégaud B; Thurin N; Moore N; Pariente A; Salvo F
    Expert Opin Drug Saf; 2017 Jun; 16(6):721-732. PubMed ID: 28490262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.